Eli Lilly and Company (LLY) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Total Assets Chart for Eli Lilly and Company

Eli Lilly and Company (LLY) total assets for FY2025 were USD 112.5B, a 42.9% change from FY2024. Eli Lilly and Company's total assets grew from USD 4.0B in 1985 to USD 112.5B in 2025 (2744.8% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 19.3%, 10-year CAGR of 12.2%, 20-year CAGR of 7.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.06T
Implied Share Price
$1191.94
Enterprise Value
$1.03T
Revenue (TTM)
$79.67B
EBITDA
$41.68B
Profit Margin
33.53%
Trailing P/E
39.22
Forward P/E
32.89
Price/Book (MRQ)
31.89
Price/Sales (TTM)
13.34
EV/EBITDA
28.52
EV/Revenue
14.30
Dividend Yield
0.55%
Book Value
$34.92
Free Cash Flow (FY2025)
$8.97B
Free Cash Flow Yield
0.84%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.